55 - Patient Recruitment & Ethics in Early Trials (S4E10)

All right, so you wanna know all about early
phase clinical trials, especially that crucial
part where researchers are bringing in the first
human participants, right? You want the nitty
gritty, how they do it ethically and effectively
without all the extra stuff. Well, you've come
to the right place. That's what the deep dive
is all about. We've gone through all the information
out there to bring you exactly that. Today we're
diving deep into patient recruitment. informed
consent, and really the whole ethical foundation
of these very first tests of new drugs in humans.
Absolutely, and to do that we're looking at transcripts
and even some real -world examples. We want to
give you a crystal clear picture of the practical
challenges and of course the critical safeguards
that are built into these early phase trials.
These first tests in humans are so important.
They are. They're the first time a drug's actually
used in people. Right. So we need to learn how
the drug acts in the body, and at the same time,
make sure we are protecting the people who have
volunteered for this research. Absolutely. OK,
so let's jump right into the first big question.
How do researchers even find the right people
for these early studies? Yeah. That's the first
hurdle, and it's a big one. It is. One of the
first things researchers have to figure out,
and we see this in our sources, is whether they
need healthy volunteers. or patient volunteers.
Right, that's a key distinction. And a lot of
it comes down to the type of drug they're testing.
Makes sense. We were looking through the transcript
from season four clinical trials, phase I and
II, deep research source, text .pdf. And it pointed
out that for a lot of those non -oncology drugs,
especially those small molecule drugs, they really
seem to prefer starting with healthy volunteers.
Why is that? Well, when you think about it, if
you're testing a new drug in people for the first
time and you want to understand its safety and
how it moves through the body, using healthy
volunteers can really make that picture a lot
clearer because, you know, they don't have an
underlying illness. So any side effects that
you observe are more likely to be directly because
of the drug itself and how the drug moves through
their body. That whole process isn't complicated
by a disease that they have. So it's about getting
that clean signal. Exactly. It's like I don't
know, if you were testing a brand new engine,
you'd probably start by putting it in a regular
car first, just to see how it runs. Exactly,
yeah. You wouldn't stick it straight into a race
car or something. You'd want that basic understanding.
Now, the same source mentions that when it comes
to oncology drugs, things often change. They
seem to shift towards using patients as volunteers.
Why is that? Well... you have to consider the
ethics of it. Giving a drug that could be quite
toxic, like some of these powerful oncology drugs,
to a healthy person who wouldn't get any direct
benefit from it, that raises some serious ethical
concerns. Definitely. So in those cases, phase
one trials usually enroll patients who already
have the disease, often those who've exhausted
all the standard treatment options. And this
way, there's at least a chance, even if it's
a small chance, that they might actually benefit
from this experimental therapy. Plus, researchers
can start to see if the drug is having any impact
on the tumor itself. It makes sense. It's about
finding that balance. And, you know, the discussion
about the failed BIA 10102474 trial, that really
highlighted this shift in thinking. regulatory
agencies are becoming much more cautious. Even
advocating for patient volunteers is the first
choice in some of these high risk, first in human
trials. It really emphasizes that we need to
be incredibly thoughtful about the risks and
the potential benefits for everyone involved.
Right, because the potential for harm to healthy
volunteers with certain classes of drugs, it's
just too great. It is. And I think this evolution
really shows that the more experience we gain
and the better we understand those risks, the
more our approach to these early trials needs.
to adapt. It has to adapt. So let's say the researchers
have decided okay we need healthy volunteers
or okay we need patients. What are some of the
practical challenges they run into when they
actually try to get people to sign up for these
phase one trials? Finding those willing participants.
Yeah getting people enrolled. We came across
this great point in clinical trials, a practical
guide to design, analysis, and reporting. And
it really stuck with me. Yeah. Choosing the right
research centers is absolutely crucial for successful
recruitment. That makes sense. If those centers
aren't in areas where you can find the right
types of patients, or if the research question
just isn't a top priority for the doctors at
those centers, well, then it's going to be really
hard to find enough participants. It's like trying
to find like a rare antique book. Okay, yeah.
In a bookstore that specializes in, I don't know,
comic books or something like that. Exactly,
you're not going to find what you need there.
You need to go to the right place. The same source
also talks about financial incentives, and it
suggests that if this study is tackling a problem
that's really important to patients and their
doctors, then those incentives might not even
be necessary. Why is that? Well, think about
it. If the research offers a real tangible hope
for tackling a serious health problem, both the
patients and their doctors are going to be highly
motivated to participate. The potential for a
positive outcome is going to be a much stronger
motivator than any financial reward. It's about
that personal stake. It's interesting, though,
because the same text also says that commercially
funded projects sometimes see higher recruitment
rates. I wonder if that could be because commercially
funded trials often have more resources available
for things like outreach and coordinating the
trial. That's a good point. Making it easier
to connect with potential participants. It's
definitely possible. More funding could absolutely
mean they're able to make more effort in finding
and reaching out to those who might be eligible.
It's all about reaching the right people. Now,
regardless of how those participants are found
or who's funding the research, there's one ethical
requirement that's always paramount. Informed
consent. Absolutely. Informed consent is the
cornerstone of ethical clinical trials, especially
in these early phases where the potential risks
might not be fully understood yet. That's right.
It's about protecting the rights and the well
-being of those people who are bravely volunteering
to be the first to receive this new drug. That's
exactly right. Now, these phase one trials are
tricky because this drug is brand new to humans.
The risks might not be completely clear. So that
puts a big ethical responsibility on the researchers
to do their due diligence, to identify and explain
those potential risks to anyone who's thinking
about participating. Absolutely. And the clinical
trials handbook actually lays out five key areas
that researchers need to consider when they're
describing those potential harms. Oh, that's
interesting. What are those five things? They
have to think about the magnitude of the potential
harm. In other words, how serious could the side
effects be? Okay. Then there's the probability
of those harms actually happening. How likely
are they? They also need to consider how invasive
the intervention is. Okay. Are we just talking
about a simple blood draw or is it a more involved
procedure? Yeah. Then they have to think about
the timing of any potential harm. Could it happen
immediately? Are we talking short term or are
there potential long -term consequences? Right.
And finally, and this is so important, they have
to think about equity issues. Yeah. Are they
asking certain groups of people, maybe those
who are already vulnerable in some way, to take
on a larger share of the risk? That's such a
crucial point about fairness, and protecting
those who might be more susceptible to harm.
Absolutely. And it's fascinating that the handbook
also points out that even placebo conditions
need to be considered for potential harm. Can
you explain that a bit more? Sure. So a placebo
itself is inactive, right? Yeah. But let's say
you have a study looking at a new drug for high
blood pressure. Now, if a participant is randomly
assigned to the placebo group, that means their
high blood pressure isn't actually being treated.
And that lack of active treatment could have
some negative health consequences for them. The
clinical trials handbook really emphasizes this,
and it raises some complex ethical questions
about how we design these trials. It does. It's
about ensuring the participants understand the
full picture when they're giving their consent.
Absolutely. So all of this, these individual
ethical considerations, it's all part of a bigger
system, right? Yes. A regulatory framework that's
designed to make sure research is done responsibly.
That's right. And while our sources don't give
us specific FDA regulation numbers about informed
consent in this exact context, the principles
we're talking about here, they're absolutely
central to the FDA's mission of protecting people
who participate in research. Absolutely. And
the FDA isn't alone in this. It's not. We also
have the ICH guidelines. The International Council
for Harmonization. Yes. And specifically, the
emerged ACHM series, which lays out an international
standard for ethical conduct in clinical trials.
So it goes beyond just the US. It does. It's
a global effort to make sure these trials are
done ethically. Exactly. And these guidelines
really reinforce the idea that informed consent
has to be given freely and based on a real understanding
of what the study is about. OK, so ethical conduct
in these early phase trials, it goes beyond just
that initial informed consent form, doesn't it?
It absolutely does. What are some of the ethical
things they need to be thinking about once the
trial is actually running? Yeah, so the clinical
trials handbook talks about this idea of minimal
risk. Minimal risk, okay. And it's defined as
basically Any potential harm from the research
should be no more likely and no worse than what
someone might experience just going about their
normal daily life. OK. Or during a routine physical
or psychological exam. Got it. But early phase
trials, especially when you're dealing with a
completely new drug, the risks could be greater
than that minimal level. So researchers constantly
have to be weighing whether the potential benefits
of the research outweigh those potential risks.
So that balance between potential harm and potential
benefit. That seems to be a core theme throughout
the ethical design of these trials. Absolutely.
The handbook is very clear on that. The research
questions have to be chosen very carefully, weighing
the potential harm against the potential benefits.
And any risks to participants must be minimized
as much as possible. At the same time, they should
be doing everything they can to maximize any
potential benefits to those participants. It
really underscores the importance of ethics throughout
the whole trial. Absolutely. It's a constant
consideration. Now, we've talked about vulnerable
populations. Yes. And I think it's worth reiterating
that whenever researchers are thinking about
involving those groups in early phase trials,
they need to be extra careful. Yes. Extra scrutiny,
extra safeguards, because those individuals could
be more susceptible to harm. Exactly. Now, our
sources also highlight the critical role of ethics
boards in this whole process. It's often called
institutional review boards or IRBs. Right, and
they're responsible for reviewing and approving
all those clinical trial protocols. They have
to make sure it's ethical. Yes. And in the season
four clinical trials phase, I and two deep research
source, Texty dot PDF, it actually mentions that
these boards can ask researchers to make changes
to their study plans. Oh, wow. If they're concerned
about safety or any ethical aspects of the research.
So it's a very important layer of protection
for those who participate in these trials. Yeah,
that independent oversight is so crucial. Now,
we wanted to see if our sources gave any specific.
real -world examples of problems that have come
up, like challenges in recruiting patients or
ethical dilemmas that have actually happened
in these early phase trials. Did we find any
concrete cases? Well, the materials we looked
at, they do a great job of laying out the principles
and the guidelines, but they don't really dive
into specific case studies that show those recruitment
problems or ethical challenges playing out in
a phase one trial. A lot of the discussion about
those real world events tends to focus more on
later stage trials or even findings from the
preclinical stage. I see. But you know, that
whole discussion about the BIA 102474 trial.
That's a powerful reminder of the serious risks
involved in those first in human studies. It
is. Especially with certain types of drugs, and
it really highlights the importance of ethical
considerations in how we design and conduct those
studies. It emphasizes how much we need to be
thinking about those things. So just because
these particular sources don't give us those
specific case studies, it doesn't mean these
issues don't happen. Exactly. It's just that
the material we were looking at had a different
focus. Alright, so let's shift gears a bit and
talk about how all of this fits into the bigger...
regulatory landscape. We've talked about the
FDA and the ICH. Could you go into more detail
about their specific roles in overseeing these
early phase trials? Sure. So in the U .S., the
FDA is the main regulatory body that oversees
clinical research. They're the ones who have
to give the green light. Yeah, exactly. And there's
a whole process for this called the investigational
new drug application or IND process. We saw this
mentioned in the season three preclinical development
and IND enabling transcripts. And also in Title
21 of the Code of Federal Regulations, Part 312,
basically anyone who wants to do clinical trials
with a new drug in the U .S. has to submit an
IND to the FDA. So it's like an application package.
Exactly. And it includes all sorts of information
about the preclinical testing they've already
done, the design of the clinical trial they're
proposing, and the qualifications of the researchers
who are going to be running this study. It's
like showing their homework. Exactly. And the
FDA carefully reviews all of this to make sure
it's safe to move ahead with testing in humans.
And they don't just approve the IND and then
wash their hands of it, right? No, no, not at
all. The FDA's involvement continues throughout
the entire clinical trial. OK. CFR Title 21 Part
312 lays this out pretty clearly. The sponsors
of the trial have this ongoing responsibility
to monitor what's happening in the study. and
to make sure everything is being done according
to the plan that was approved, following all
the regulations and ethical guidelines. And if
they find out that... an investigator isn't complying
with those requirements, they have to take action.
Like step in and fix things. Exactly. They might
have to ensure compliance or even remove that
investigator from the study altogether. And they're
required to report that to the FDA. So there's
a lot of accountability built in. There is. It
really highlights how important it is to maintain
ethical and scientific rigor throughout the entire
trial. It does. Now, what about the International
Council for Harmonization or ICH? Right. How
do their guidelines contribute to the ethical
conduct of these early trials? Well, the ICH
guidelines, which we see in the merged ICHM series,
they're all about creating a harmonized approach
to the scientific and ethical standards for clinical
trials globally. So it's about consistency across
different countries. Exactly. Now, FDA regulations
are law in the U .S., but the ICH guidelines,
they represent a consensus among regulatory authorities
from the U .S. Europe. Japan, and other parts
of the world. OK. So by following these guidelines,
researchers can be more confident that their
clinical trial data will be accepted by regulatory
agencies in different countries. That's huge
for global drug development. It is. And these
guidelines cover a really wide range of topics,
including detailed principles of good clinical
practice. Good clinical practice. Yes. And that
covers all sorts of ethical considerations for
how trials should be designed, conducted, recorded,
and reported. So to wrap things up, we've really
covered a lot of ground today. We have. We've
got a much clearer picture now of what it takes
to find the right participants for those early
phase drug tests. Hopefully. And why it's so
important to make sure those volunteers truly
understand what they're signing up for with informed
consent. Absolutely. And we've talked about the
ethical principles that are guiding this whole
process, all under the watchful eye of regulators
like the FDA. And those global standards that
are being promoted by the ICH. It's a complex
system, but it's designed to ensure that these
trials are done safely and ethically. It is these
early phase clinical trials. They're really the
first step on the road to potentially life -saving
therapies for people who desperately need them.
They are. So understanding the ethics behind
them, how recruitment works, and the regulatory
context is essential for anyone who's involved
in this world of medical innovation. It is. So
here's a final thought for you to ponder as you
go about your day. Okay. We have this incredible
need for new medical treatments. We do. Often
for really serious, life -threatening conditions.
But at the same time, we have the strict ethical
standards that have to be upheld throughout the
development of those treatments. Think about
that balance, that tension between the urgent
need for those new therapies and the absolute
necessity of doing things the right way ethically.
How does that influence your perspective on medical
breakthroughs? How do those breakthroughs actually
happen? It's a really important question to consider.
It is. And it's a complex one. And I hope this
deep dive has given you some new insights to
consider. Me too. Thanks for joining us today.
Keep those questions coming. Absolutely. Keep
learning.